metiamide and Remission--Spontaneous

This paper presents the results of a pilot study to investigate whether the administration of a nocturnal dose of metiamide (the first orally active H2 receptor antagonist) would prevent or delay the relapse of duodenal ulceration after initial ulcer healing. Sixteen patients took part in a double-blind trial to compare metiamide (400 mg) with placebo. Endoscopically confirmed duodenal ulcer relapses occurred in two out of eight on metiamide and six out of eight on placebo. There was a significant prolongation of remission in those in those on the active drug with an apparent reduction in duodenitis.

Topics: Adult; Aged; Clinical Trials as Topic; Duodenal Diseases; Duodenal Ulcer; Enteritis; Humans; Metiamide; Middle Aged; Recurrence; Remission, Spontaneous; Thiourea; Time Factors

The histamine H2-receptor antagonist metiamide is an inhibitor of endogenous and stimulated gastric-acid secretion. It appears to have therapeutic possibilities in duodenal-ulcer disease. Three patients exhibiting the Zollinger-Ellison syndrome have been treated with this drug for six months or more. Rapid symptomatic improvement occurred in each case, followed by ulcer healing. There were also reductions in gastric secretion and consistent changes in the fasting serum-gastrin concentration. On patient relapsed temporarily during therapy. There have been no side effects. It is concluded that, in the short term, metiamide is of benefit in the Zollinger-Ellison syndrome.

Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Gastric Juice; Gastrins; Humans; Male; Metiamide; Middle Aged; Remission, Spontaneous; Thiourea; Zollinger-Ellison Syndrome

The clinical, endoscopic, and biochemical effects of metiamide, a histamine H2-receptor antagonist, in therapeutic dosage have been studied in a 28-day open trial in patients with duodenal ulcer disease. A good symptomatic response, combined with a 72% ulcer healing rate was observed. There were small but significant rises in plasma creatinine, serum glutamic oxaloacetic transaminase, and serum lactate dehydrogenase during treatment. Small quantities of amino acids appeared in the urine, and the heart size increased slightly. It is concluded that histamine H2-receptor antagonism may be an important therapeutic approach to duodenal ulcer disease.

Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Duodenal Ulcer; Follow-Up Studies; Humans; Metiamide; Middle Aged; Remission, Spontaneous; Thiourea